SL Science Data Shows Immune Cells Attack Drug-Resistant Brain Tumors
Preclinical findings suggest γδ T cells can selectively destroy glioblastoma cells that survive standard chemotherapy and fuel relapse.
SL Science presented preclinical research at the 85th Annual Meeting of the Japanese Cancer Association demonstrating that gamma-delta (γδ) T cells can preferentially target chemotherapy-resistant glioblastoma tumor cells, according to data released by the company.
The findings center on MGMT-positive tumor cells, a specific cellular population known to withstand standard chemotherapy treatments. Because these cells survive conventional therapy, they are widely regarded as a primary driver of disease recurrence in glioblastoma patients, one of the most lethal and difficult-to-treat brain cancers.
Read more HouseCanary Wins Court Approval for Chapter 11 Reorganization Financing →
The preclinical data suggests the γδ T cell-based approach may address a critical gap in glioblastoma treatment — the inability of standard regimens to eliminate the resistant cell population most responsible for the cancer returning after initial therapy. If validated in further studies, a therapy capable of selectively destroying MGMT-positive cells could represent a meaningful advance in managing recurrent disease.
Glioblastoma carries a grim prognosis, with most patients experiencing relapse even after aggressive surgery, radiation, and chemotherapy. The persistence of MGMT-positive cells following treatment has long been identified as a central obstacle to achieving durable remissions, making them a high-priority target for next-generation oncology research.
The presentation at one of Japan's most prominent oncology conferences underscores growing international interest in γδ T cell immunotherapy as a potential complement or alternative to existing cancer treatment protocols. Continue reading at GlobeNewswire - Industry News on Financial Services.
